APLS · Categories · Coverage
APLS - Analyst coverage initiated
Apellis Pharmaceuticals Inc. (APLS) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for APLS
- Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price targetRoth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00
- Barclays initiated coverage on Apellis Pharmaceuticals with a new price targetBarclays initiated coverage of Apellis Pharmaceuticals with a rating of Equal Weight and set a new price target of $24.00
- Wolfe Research initiated coverage on Apellis PharmaceuticalsWolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform
- Wells Fargo initiated coverage on Apellis Pharmaceuticals with a new price targetWells Fargo initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $32.00
- Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price targetCantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00
- Morgan Stanley initiated coverage on Apellis Pharmaceuticals with a new price targetMorgan Stanley initiated coverage of Apellis Pharmaceuticals with a rating of Equal-Weight and set a new price target of $31.00
- RBC Capital Mkts initiated coverage on Apellis Pharmaceuticals with a new price targetRBC Capital Mkts initiated coverage of Apellis Pharmaceuticals with a rating of Sector Perform and set a new price target of $25.00
- Scotiabank initiated coverage on Apellis PharmaceuticalsScotiabank initiated coverage of Apellis Pharmaceuticals with a rating of Sector Outperform
- William Blair initiated coverage on Apellis PharmaceuticalsWilliam Blair initiated coverage of Apellis Pharmaceuticals with a rating of Outperform
- Piper Sandler initiated coverage on Apellis Pharmaceuticals with a new price targetPiper Sandler initiated coverage of Apellis Pharmaceuticals with a rating of Neutral and set a new price target of $46.00
- Goldman initiated coverage on Apellis Pharmaceuticals with a new price targetGoldman initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $74.00
- Mizuho initiated coverage on Apellis Pharmaceuticals with a new price targetMizuho initiated coverage of Apellis Pharmaceuticals with a rating of Neutral and set a new price target of $42.00
- H.C. Wainwright initiated coverage on Apellis Pharmaceuticals with a new price targetH.C. Wainwright initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $75.00
- Wells Fargo initiated coverage on Apellis Pharmaceuticals with a new price targetWells Fargo initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $84.00
- Jefferies initiated coverage on Apellis Pharmaceuticals with a new price targetJefferies initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $74.00
- UBS initiated coverage on Apellis Pharmaceuticals with a new price targetUBS initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $82.00
- Goldman Sachs initiated coverage on Apellis Pharmaceuticals with a new price targetGoldman Sachs initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $130.00